<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="discussion" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id>
<journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id>
<journal-title-group>
<journal-title>EBioMedicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2352-3964</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27397513</article-id>
<article-id pub-id-type="pmc">4972570</article-id>
<article-id pub-id-type="publisher-id">S2352-3964(16)30290-0</article-id>
<article-id pub-id-type="doi">10.1016/j.ebiom.2016.06.036</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Commentary</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurons Derived From Patient-Specific Induced Pluripotent Stem Cells: a Promising Strategy Towards Developing Novel Pharmacotherapies for Autism Spectrum Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mokhtari</surname>
<given-names>Ryan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lachman</surname>
<given-names>Herbert M.</given-names>
</name>
<email>herb.lachman@einstein.yu.edu</email>
<xref ref-type="corresp" rid="cr0005">⁎</xref>
</contrib>
</contrib-group>
<aff id="af0005">Albert Einstein College of Medicine 1300 Morris Park Ave. Bronx, New York 10461</aff>
<author-notes>
<corresp id="cr0005"><label>⁎</label>Corresponding author at: Department of Psychiatry.Department of Psychiatry <email>herb.lachman@einstein.yu.edu</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>30</day>
<month>6</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>9</volume>
<fpage>21</fpage>
<lpage>22</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>6</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 Published by Elsevier B.V.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder></copyright-holder>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<kwd-group id="ks0005">
<title>Keywords</title>
<kwd>Induced pluripotent</kwd>
<kwd>Neuron</kwd>
<kwd>Screening</kwd>
<kwd>Shank3</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>One of the primary obstacles facing researchers interested in autism spectrum disorders (ASD) and other neuropsychiatric disorders is the lack of direct access to live brain tissue. Animal models can be used as a surrogate. However, data from the mouse and human ENCODE projects show substantial differences in regulatory domains, which suggests that some unique pathophysiological features may exist in humans, and that novel pharmacotherapies may not necessarily work in both species (<xref ref-type="bibr" rid="bb0025">Kavanagh et al., 2013</xref>, <xref ref-type="bibr" rid="bb0050">Yue et al., 2014</xref>). However, the introduction of induced pluripotent stem (iPS) cell technology has provided a promising platform for disease modeling and drug screening that addresses these obstacles (<xref ref-type="bibr" rid="bb0005">Brennand et al., 2011</xref>, <xref ref-type="bibr" rid="bb0035">Pedrosa et al., 2011</xref>, <xref ref-type="bibr" rid="bb0055">Zhao et al., 2012</xref>).</p>
<p>The challenge of developing effective pharmacotherapies for ASD is also limited by our incomplete understanding of its etiology, as well as genetic and clinical heterogeneity. However, despite the complex genetic underpinning of ASD, the clinical phenotype can be attributed to a distinct genetic abnormality in a significant proportion of patients (<xref ref-type="bibr" rid="bb0040">Persico and Napolioni, 2013</xref>). This subgroup of ASD individuals can be a helpful resource for developing iPS cell-derived neurons to identify dysfunctional underlying biological pathways, as well as for the development of personalized therapeutic interventions targeting specific genetic abnormalities.</p>
<p>One such gene is <italic>SHANK3</italic>, one of several ASD risk genes that code for synaptic proteins. SHANK3 is a scaffolding protein that helps form the post-synaptic density (PSD), which plays a critical role in regulating glutamatergic transmission. <italic>De novo</italic> loss-of-function mutations have been identified in some ASD individuals, and is believed to be a key gene involved in the behavioral phenotypes associated with 22q13 deletion syndrome (DS) (<xref ref-type="bibr" rid="bb0015">Durand et al., 2007</xref>, <xref ref-type="bibr" rid="bb0020">Harony-Nicolas et al., 2015</xref>). <italic>SHANK3</italic> haploinsufficient neurons derived from patients with 22q13DS display decreased glutamatergic transmission, which can be rescued by a <italic>SHANK3</italic> cDNA expression vector (<xref ref-type="bibr" rid="bb0045">Shcheglovitov et al., 2013</xref>). Similarly, autistic phenotypes in adult mice can be rescued after restoring <italic>SHANK3</italic> expression (<xref ref-type="bibr" rid="bb0030">Mei et al., 2016</xref>).</p>
<p>In light of the preceding findings, the study by Darville and colleagues (<xref ref-type="bibr" rid="bb0010">Darville et al., 2016</xref>) is timely. They explored the therapeutic potential of more than 200 pharmacological agents, using neurons differentiated from iPS cells derived from ASD individuals heterozygous for <italic>SHANK3</italic> null mutations. Darville et al. applied a comprehensive step-wise approach to identify potentially effective compounds. Using a qPCR-based high throughput screening (HTS) method, they quantified the relative expression of <italic>SHANK3</italic> after treating day-14 neurons with the test compounds, some of which were FDA-approved psychotropic drugs.</p>
<p>The authors found six compounds that increased <italic>SHANK3</italic> mRNA in a concentration-dependent manner, of which three were validated at the protein level: lithium, valproic acid (VPA), and fluoxetine. They performed a quantitative immunostaining analysis of synapses using pre-synaptic and post-synaptic neuronal markers. Only neurons treated with lithium and VPA showed evidence of staining for all the synaptic markers - indicative of increased <italic>SHANK3</italic> activity. Recording spontaneous calcium oscillations (SCO) in the neurons at a later stage revealed that only lithium and VPA increased their intensity and frequency. Transcriptome analysis demonstrated that, compared to VPA, lithium targets a narrower range of neuronal and synaptic genes, which perhaps could translate into a more specific and safer treatment.</p>
<p>To identify molecular pathways that lithium and VPA possibly share in their effect on <italic>SHANK3</italic> expression, the authors hypothesized that Glycogen Synthase Kinase 3 (GSK3) and/or class I Histone Deacetylase (HDAC) could be the possible common targets. Treating the iPS cell-derived neurons with two agents, CHIR99021 (a selective GSK3 inhibitor) and Trichostatin A (a selective HDAC inhibitor) revealed that only the latter agent increased <italic>SHANK3</italic> mRNA. Similarly, a pathway enrichment analysis on genes regulated by lithium and VPA showed that histone modifications, but not GSK3 <italic>per se</italic>, is the more likely mechanism shared by these two drugs in the upregulation of <italic>SHANK3</italic>.</p>
<p>Another important feature of this study was the use of a human embryonic stem cell (hESC) line as a control. When studying epigenetic phenomena in iPS cells, such as involvement of HDAC in a drug response, it is important to consider the fact that epigenetic differences may exist in iPS cell lines related to reprogramming and cell of origin, which can theoretically affect experimental findings. Thus, the observation by Darville et al. that the response to lithium and valproate was the same in the hESC line and iPS cells is significant.</p>
<p>Finally, the study is complemented by a trial of lithium administered to one of the ASD patients whose cells were used in the screening study. The authors reported some improvement in the clinical presentation after one year, based on several quantitative scales. However, worsening of some measures (<italic>e.g.</italic>, ADHD symptoms) was also observed. The authors appropriately caution that at this stage, the use of lithium to treat patients with <italic>SHANK3</italic> haploinsufficiency is premature. Nevertheless, this study is an interesting illustration of the potential use of neuronal cells derived from iPS cells for high-throughput drug screening, and the development of personalized medicine for complex neuropsychiatric disorders.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bb0005">
<element-citation id="rf0005" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennand</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Modelling schizophrenia using human induced pluripotent stem cells</article-title>
<source/>Nature
          <volume>473</volume>
<issue>7346</issue>
<year>2011</year>
<fpage>221</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="pmid">21490598</pub-id>
</element-citation>
</ref>
<ref id="bb0010">
<element-citation id="rf0010" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darville</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Human pluripotent stem cell-derived cortical neurons for high throughput medication screening in autism: a proof of concept study in <italic>SHANK3</italic> haplo-insufficiency syndrome</article-title>
<source/>EBiomedicine
          <year>2016</year>
</element-citation>
</ref>
<ref id="bb0015">
<element-citation id="rf0015" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durand</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Mutations in the gene encoding the synaptic scaffolding protein <italic>SHANK3</italic> are associated with autism spectrum disorders</article-title>
<source/>Nat. Genet.
          <volume>39</volume>
<issue>1</issue>
<year>2007</year>
<fpage>25</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">17173049</pub-id>
</element-citation>
</ref>
<ref id="bb0020">
<element-citation id="rf0020" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harony-Nicolas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>De Rubeis</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kolevzon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buxbaum</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Phelan McDermid syndrome: from genetic discoveries to animal models and treatment</article-title>
<source/>J. Child Neurol.
          <volume>30</volume>
<issue>14</issue>
<year>2015</year>
<fpage>1861</fpage>
<lpage>1870</lpage>
<pub-id pub-id-type="pmid">26350728</pub-id>
</element-citation>
</ref>
<ref id="bb0025">
<element-citation id="rf0025" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavanagh</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>The ENCODE project: implications for psychiatric genetics</article-title>
<source/>Mol. Psychiatry
          <volume>18</volume>
<year>2013</year>
<fpage>540</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">23478746</pub-id>
</element-citation>
</ref>
<ref id="bb0030">
<element-citation id="rf0030" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mei</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Adult restoration of <italic>SHANK3</italic> expression rescues selective autistic-like phenotypes</article-title>
<source/>Nature
          <volume>530</volume>
<issue>7591</issue>
<year>2016</year>
<fpage>481</fpage>
<lpage>484</lpage>
<pub-id pub-id-type="pmid">26886798</pub-id>
</element-citation>
</ref>
<ref id="bb0035">
<element-citation id="rf0035" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pedrosa</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells</article-title>
<source/>J. Neurogenet.
          <volume>25</volume>
<issue>3</issue>
<year>2011</year>
<fpage>88</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="pmid">21797804</pub-id>
</element-citation>
</ref>
<ref id="bb0040">
<element-citation id="rf0040" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persico</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Napolioni</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Autism genetics</article-title>
<source/>Behav. Brain Res.
          <volume>251</volume>
<year>2013</year>
<fpage>95</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="pmid">23769996</pub-id>
</element-citation>
</ref>
<ref id="bb0045">
<element-citation id="rf0045" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shcheglovitov</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title><italic>SHANK3</italic> and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients</article-title>
<source/>Nature
          <volume>503</volume>
<issue>7475</issue>
<year>2013</year>
<fpage>267</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="pmid">24132240</pub-id>
</element-citation>
</ref>
<ref id="bb0050">
<element-citation id="rf0050" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Mouse ENCODE consortium: a comparative encyclopedia of DNA elements in the mouse genome</article-title>
<source/>Nature
          <volume>515</volume>
<year>2014</year>
<fpage>355</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="pmid">25409824</pub-id>
</element-citation>
</ref>
<ref id="bb0055">
<element-citation id="rf0055" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>W.N.</given-names>
</name>
</person-group>
<article-title>A high-throughput screen for Wnt/β-catenin signaling pathway modulators in human iPSC-derived neural progenitors</article-title>
<source/>J. Biomol. Screen.
          <volume>17</volume>
<issue>9</issue>
<year>2012</year>
<fpage>1252</fpage>
<lpage>1263</lpage>
<pub-id pub-id-type="pmid">22923789</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>